Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic/pharmacodynamic model

Evaluation of theIn VitroActivity of Voriconazole As Predictive ofIn VivoOutcome in a Murine Aspergillus fumigatus Infection Model

(2013) Valentina Salas et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Relationship between Trough Plasma and Epithelial Lining Fluid Concentrations of Voriconazole in Lung Transplant Recipients

(2013) Siow-Chin Heng et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Inhibitory and Fungicidal Effects of Antifungal Drugs against Aspergillus Species in the Presence of Serum

(2013) Antigoni Elefanti et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

EUCAST Technical Note on Voriconazole and Aspergillus spp.

(2013) W.W. Hope et al.   CLINICAL MICROBIOLOGY AND INFECTION

The cdr1B efflux transporter is associated with non-cyp51a-mediated itraconazole resistance in Aspergillus fumigatus 

(2013) Marcin G. Fraczek et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Growth ofAspergillusin blood cultures: proof of invasive aspergillosis in patients with chronic obstructive pulmonary disease?

(2013) Maddalena Giannella et al.   MYCOSES

Epidemiological Cutoff Values for Azoles and Aspergillus fumigatus Based on a Novel Mathematical Approach Incorporatingcyp51ASequence Analysis

(2012) J. Meletiadis et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroPharmacokinetic/Pharmacodynamic Modeling of Voriconazole Activity against Aspergillus Species in a NewIn VitroDynamic Model

(2012) R. Al-Saigh et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacodynamics of Voriconazole in a Dynamic In Vitro Model of Invasive Pulmonary Aspergillosis: Implications for In Vitro Susceptibility Breakpoints

(2012) Adam R. Jeans et al.   JOURNAL OF INFECTIOUS DISEASES

Protein Binding: Do We Ever Learn?

(2011) Markus A. Zeitlinger et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacodynamic Effects of Simulated Standard Doses of Antifungal Drugs against Aspergillus Species in a NewIn VitroPharmacokinetic/Pharmacodynamic Model

(2011) Joseph Meletiadis et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Observational Study of the Clinical Efficacy of Voriconazole and Its Relationship to Plasma Concentrations in Patients

(2011) Peter F. Troke et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria

(2011) Michael A. Pfaller et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Azole resistance inAspergillus fumigatus: a new challenge in the management of invasive aspergillosis?

(2011) Eveline Snelders et al.   Future Microbiology

Impact of cyp51A Mutations on the Pharmacokinetic and Pharmacodynamic Properties of Voriconazole in a Murine Model of Disseminated Aspergillosis

(2010) E. Mavridou et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery

(2010) Dennis A. Smith et al.   NATURE REVIEWS DRUG DISCOVERY

Concentrations of Voriconazole in Healthy and Inflamed Lung in Rats

(2009) C. Joukhadar et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Combination Therapy in Treatment of Experimental Pulmonary Aspergillosis: In Vitro and In Vivo Correlations of the Concentration- and Dose- Dependent Interactions between Anidulafungin and Voriconazole by Bliss Independence Drug Interaction Analysis

(2009) V. Petraitis et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetics and Pharmacodynamics of a Novel Triazole, Isavuconazole: Mathematical Modeling, Importance of Tissue Concentrations, and Impact of Immune Status on Antifungal Effect

(2009) P. A. Warn et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In vitro pharmacodynamic models to determine the effect of antibacterial drugs

(2009) J. Gloede et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Patterns of Susceptibility of Aspergillus Isolates Recovered from Patients Enrolled in the Transplant-Associated Infection Surveillance Network

(2009) J. W. Baddley et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Antifungal Therapeutic Drug Monitoring: Established and Emerging Indications

(2008) D. Andes et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Changes in causes of death over time after treatment for invasive aspergillosis

(2008) John R. Wingard et al.   CANCER

Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America

(2008) Thomas J. Walsh et al.   CLINICAL INFECTIOUS DISEASES

Epidemiology and Outcome of Invasive Fungal Infection in Adult Hematopoietic Stem Cell Transplant Recipients: Analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance Registry

(2008) D. Neofytos et al.   CLINICAL INFECTIOUS DISEASES

Free renal levels of voriconazole determined by microdialysis in healthy and Candida sp.-infected Wistar rats

(2008) Bibiana Verlindo de Araujo et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Activities of voriconazole, itraconazole and amphotericin B in vitro against 590 moulds from 323 patients in the voriconazole Phase III clinical studies

(2008) A. Espinel-Ingroff et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Voriconazole Therapeutic Drug Monitoring in Patients with Invasive Mycoses Improves Efficacy and Safety Outcomes

(2007) A. Pascual et al.   CLINICAL INFECTIOUS DISEASES